Nabilone for Agitation in Frontotemporal Dementia

Key facts

Sponsor

Simon Ducharme, MD

Intervention

Nabilone(drug)

Enrollment

45 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (7)

• University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada
• Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada
• Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
• Baycrest Hospital, University of Toronto, Toronto, Ontario, Canada
• Western Hospital - University of Toronto, Toronto, Ontario, Canada
• CHU de Québec, Université Laval, Laval, Quebec, Canada
• The Douglas Research Centre, Montreal, Quebec, Canada

Collaborators

Alzheimer's Drug Discovery Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Behavioral variant of frontotemporal dementia

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07531732
  Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE2NCT06604520
  Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
  Johns Hopkins University
• RECRUITINGNANCT06706687
  A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated Approach
  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• ENROLLING BY INVITATIONNCT04680130
  Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
  Mayo Clinic

See all trials for Behavioral variant of frontotemporal dementia →